NGS Streamlines Biomarker Testing in Solid Tumors
According to experts, next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors.
Chen, PharmD, MS, BCOP, CPP, discusses how NGS enhances biomarker testing and treatment planning in solid tumors.
- Experts involved in the discussion include Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH; and Mark Agulnik, MD.
- Others who contributed to the conversation are Mrinal M. Zuckerman, MD; Daniel Lefler, MD; and Naval G. Daver, MD.
- Additional participants include Jessica Altman, MD; Amir T. Roboz, MD; and Joshua Zeidner, MD.
Author's summary: NGS enhances biomarker testing in solid tumors.